Corbus Pharmaceuticals Holdings (CRBP) Amortization of Deferred Charges (2021 - 2022)

Corbus Pharmaceuticals Holdings' (CRBP) quarterly Amortization of Deferred Charges came in at $189821.0 in Q4 2022, down 31.74% year-on-year from $278088.0 in Q4 2021, and up 3.16% quarter-over-quarter from $184004.0 in Q3 2022.

Corbus Pharmaceuticals Holdings (CRBP) Amortization of Deferred Charges (2021 - 2022) Analysis & Trends

Corbus Pharmaceuticals Holdings' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $189821.0 for Q4 2022.

  • On a quarterly basis, Amortization of Deferred Charges fell 31.74% year-over-year to $189821.0 in Q4 2022; TTM through Dec 2022 was $703604.0, a N/A change from a year earlier, with the FY2022 full-year figure at $724858.0, up 13.36% from the prior year.
  • Amortization of Deferred Charges climbed to $189821.0 in Q4 2022 per CRBP's latest filing, from $184004.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $278088.0 in Q4 2021 and bottomed at $51691.0 in Q3 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn
7 Belite Bio 62.84 Bn 62.84 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 Corbus Pharmaceuticals Holdings 114.70 Mn 86.89 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 189,821.00
Dec 31, 2022 189,821.00
Sep 30, 2022 184,004.00
Sep 30, 2022 184,004.00
Dec 31, 2021 278,088.00
Dec 31, 2021 278,088.00
Sep 30, 2021 51,691.00
Sep 30, 2021 51,691.00